Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
11
1
1
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
45%
5 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Phase I Study of LX22001 for Injection in Healthy Subjects
Role: lead
Efficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional Constipation
Role: lead
Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori
Role: lead
Drug Interaction Study Between Tegoprazan, Bismuth, Amoxicillin and Clarithromycin
Role: lead
Mass Balance and Biotransformation Study of [14C]LXI-15028 in Humans
Role: lead
A Phase I Study of LX-039 Tablets
Role: lead
Efficacy and Safety of LXI-15028 Comparing With Lansoprazole in the Treatment of Duodenal Ulcer
Role: lead
A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors
Role: lead
Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive Esophagitis
Role: lead
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Phase III Study to Evaluate the Efficacy and Safety of LXI-15028 in Non-erosive Reflux Disease in Chinese Patients for 4 Weeks
Role: lead
A Phase I Study of LuoXin Innovate (LXI-15028) in Healthy Chinese Subjects to Evaluate the Pharmacokinetics, Safety and Tolerability.
Role: lead
All 11 trials loaded